<DOC>
	<DOCNO>NCT02288481</DOCNO>
	<brief_summary>The objective study evaluate safety tolerability single oral dos TBA‐354 administer healthy adult subject .</brief_summary>
	<brief_title>A Phase 1 Study Evaluate Safety , Tolerability , Pharmacokinetics TBA-354 Healthy Adult Subjects</brief_title>
	<detailed_description>This randomize , double‐blind , placebo‐controlled , single ascend dose study conduct one study center United States . Six ( 6 ) cohort 8 subject ( 6 active 2 placebo ) , one cohort cross assess food effect , plan evaluation . Subjects participate one cohort . Safety assess throughout study ; serial ECGs serial blood sample collect safety PK assessment TBA‐354 . Dose escalation next cohort ( i.e. , dose level ) take place Sponsor , conjunction Principal Investigator , determine adequate safety , tolerability PK previous cohort demonstrate permit proceed next cohort . Upon review cohort data , Sponsor , conjunction Principal Investigator , may decide : 1 . Escalate dose plan . 2 . Evaluate intermediate dose level prior proceed next plan dose level concern arise sign symptom warrant cease escalation describe . 3 . Repeat give dose level new cohort subject . 4 . Halt study . Blinded interim PK analysis perform dose escalation decision , select intermediate dose food effect cohort , reconsider sample time point study progress . Subjects house Celerion clinic least 24 hour prior ( Day ‐2 ) , 48 hour dose . Subjects return subsequent follow safety PK assessment Days 4 7 contacted via phone call follow‐up question adverse event 7 day later ( Study Day 14 ) . One cohort return washout least 14 day five half‐lives ( whichever longer ) fast dose receive intermediate dose ( TBD mg ) feed condition .</detailed_description>
	<mesh_term>Tuberculosis</mesh_term>
	<criteria>Subjects must fulfill follow inclusion criterion none exclusion criterion eligible participation study , unless otherwise specify . Subjects must continue meet inclusion criterion able participate Food Effect study . 1 . Healthy adult male female non‐childbearing potential , 19 50 year age ( inclusive ) time screen . 2 . Body mass index ( BMI ) ≥ 18.5 ≤ 32.0 ( kg/m2 ) body weight less 50 kg . 3 . Medically healthy clinically significant screen result ( e.g. , laboratory profile , medical history , vital sign , electrocardiogram ( ECGs ) , physical examination ) deem Principal Investigator . 4 . No use tobacco nicotine containing product ( include smoke cessation product ) , minimum 6 month prior dose . 5 . Females non‐childbearing potential undergone one follow sterilization procedure least 6 month prior dose : i. Hysteroscopic sterilization ii . Bilateral tubal ligation bilateral salpingectomy iii . Hysterectomy iv . Bilateral oophorectomy v. postmenopausal amenorrhea least 1 year prior first dose serumfollicle‐stimulating hormone ( FSH ) level consistent postmenopausal status screening . 6 . Non‐vasectomized male ( male vasectomize less 120 day prior study start ) , must agree follow study participation 90 day follow last administration study drug : 1. use condom spermicide engage sexual activity sexually abstinent 2. donate sperm time . In event sexual partner surgically sterile , use condom spermicide necessary . None restriction list required vasectomized male whose procedure perform 120 day prior study start . 7 . Willing answer inclusion exclusion criterion questionnaire check‐in . 8 . Subject understands study procedure provide write informed consent trial . 9 . Be able comply protocol assessment therein . Subjects exclude study evidence follow criterion screen check‐in , appropriate . Subjects must continue meet none Exclusion Criteria order participate Food Effect study . 1 . History presence significant cardiovascular , pulmonary , hepatic , renal , hematological , gastrointestinal , endocrine , immunologic , dermatologic , neurological , psychiatric disease . 2 . History illness , opinion Principal Investigator , might confound result study pose additional risk subject participation study . 3 . Surgery within past 90 day prior dose determine Principal Investigator clinically relevant . 4 . History presence alcoholism drug abuse within past 2 year . 5 . Hypersensitive idiosyncratic reaction compound related TBA‐354 ( e.g. , nitroimidazoles metronidazole , etc. ) . 6 . Female subject pregnant lactating . 7 . Positive result urine drug/alcohol screen screen check‐in . 8 . Positive urine cotinine screening . 9 . Positive result screen Human Immunodeficiency Virus ( HIV ) , Hepatitis B Surface Antigen ( HBsAg ) , Hepatitis C antibody ( HCV ) . 10 . Seated blood pressure le 90/40 mmHg great 140/90 mmHg screening . 11 . Heart rate lower 40 bpm high 99 bpm screening . 12 . Any clinically significant ECG abnormality Screening ( deem Principal Investigator Sponsor 's Medical Monitor ) . NOTE : The follow consider clinically significant without consult Sponsor 's Medical Monitor : . Mild first degree A‐V block ( P‐R interval &lt; 0.23 sec ) ii . Right leave axis deviation iii . Incomplete right bundle branch block iv . Isolated leave anterior fascicular block ( leave anterior hemiblock ) young athletic subject 13 . QTcF interval &gt; 450 msec male &gt; 470 msec female ( average value replicate ECG screen Check‐In ) , history prolong QT syndrome . 14 . Family history Long‐QT Syndrome sudden death without precede diagnosis condition could causative sudden death ( know coronary artery disease , congestive heart failure terminal cancer ) . 15 . History one combination , follow : 1 . Seizures seizure disorder , ( exclude febrile seizure childhood ) . 2 . Brain trauma brain surgery . 3 . Any serious disorder CNS relate neurological system , particularly one may lower seizure threshold . 16 . Use prescription medication within 14 day prior dose . 17 . Use over‐the‐counter ( OTC ) medication , include herbal product vitamin , within 7 day prior dose . Up 2 gram per day acetaminophen allow discretion Principal Investigator . 18 . Use drug substance know significant inhibitor CYP enzymes and/or significant inhibitor substrates P‐gp and/or OATP within 14 day prior first dose study drug . 19 . Use drug substance know inducer CYP enzymes and/or P‐gp , include St. John 's Wort , within 28 day prior first dose study drug . 20 . Use drug substance know low seizure threshold . 21 . Blood donation significant blood loss within 56 day prior dose . 22 . Plasma donation within 7 day prior dose . 23 . Participation another clinical trial within 28 day prior dose . 24 . Prior treatment investigational product PA‐824 OPC‐67683 . 25 . Consumption follow prior dose period : 1 . Alcohol 48 hour prior dose 2 . Grapefruit/Mandarin Oranges 10 day prior dose 3 . Caffeine/Xanthine 24 hour prior dose</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>March 2016</verification_date>
	<keyword>Tuberculosis</keyword>
	<keyword>TBA-354</keyword>
	<keyword>Pulmonary Tuberculosis</keyword>
	<keyword>TB</keyword>
</DOC>